A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Burnett, Alan K., Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert K., Wheatley, Keith·2007·Cancer

DOI 10.1002/cncr.22496

Cited by (619)

Items 201–300 of 619

Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.
Joseph M. Brandwein, Lalit Saini, Michelle N. Geddes, Dimas Yusuf, Fei Liu, Kiersten Schwann, Alkarim Billawala, Christopher Westcott, Jessica A. Kurniawan, Winson Y. Cheung · 2020 · PubMed Central
Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia
Fang‐Liang Huang, Sheng‐Jie Yu, Chia‐Ling Li · 2021 · Cancer Control
5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline
Rena J. Buckstein, Karen W L Yee, Richard A. Wells · 2010 · Cancer Treatment Reviews
Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia
Mikkael Aaron Sekeres, David P. Steensma · 2012 · Journal of Clinical Oncology
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Mikkael Aaron Sekeres, Pau Montesinos, Jan Novák, Jianxiang Wang, Deepa Jeyakumar, Benjamin Kent Tomlinson, Jiřı́ Mayer, Erin Jou, Tadeusz Robak, David Christopher Taussig et al. · 2023 · Leukemia
AML: New Drugs but New Challenges
Alan K. Burnett, Richard Maury Stone · 2020 · Clinical Lymphoma Myeloma & Leukemia
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
Hartmut Döhner, Argiris S. Symeonidis, Dries Deeren, Judit Demeter, Miguel Ángel Sanz, Αchilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee‐Je Kim et al. · 2021 · HemaSphere
“I Am Older, Not Elderly,” Said the Patient With Acute Myeloid Leukemia
Charles Alan Schiffer · 2009 · Journal of Clinical Oncology
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Jorge Labrador, Miriam Saiz‐Rodríguez, Dunia de Miguel, Almudena de Laiglesia, Carlos Rodríguez‐Medina, María‐Belén Vídriales, Manuel Pérez‐Encinas, María‐José Sánchez‐Sánchez, Rebeca Cuello, Alicia Roldán et al. · 2022 · Cancers
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
Rachid Baz, Cristina P. Rodriguez, Alex Z. Fu, Rony M. Abou Jawde, Matt E Kalaycio, Anjali S. Advani, Ronald M. Sobecks, Mikkael Aaron Sekeres · 2007 · Cancer
Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia
Ibrahin Aldoss, Lisa Mark, Janice Vrona, Laleh Ramezani, Ilene Ceil Weitz, Ann M. Mohrbacher, Dan Douer · 2014 · Annals of Hematology
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia
Mikkael Aaron Sekeres, Jaroslaw Pawel Maciejewski, Harry Paul Erba, Manuel Geroy Afable, Ricki K. Englehaupt, Ronald M. Sobecks, Anjali S. Advani, Sherry Seel, Josephine Chan, Matt E Kalaycio · 2010 · Cancer
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
Jing Li, Ju Gao, Ansheng Liu, Wei Liu, Hao Xiong, Changda Liang, Yongjun Fang, Yunpeng Dai, Jingbo Shao, Hui Yu et al. · 2023 · Journal of Clinical Oncology
Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy
Laura Elizabeth Finn, Lisa Sproat, Michael G. Heckman, Liuyan Jiang, Nancy N. Diehl, Rhett P. Ketterling, Raoul Tibes, Ricardo Valdez, James M. Foran · 2015 · Cancer Epidemiology
AML in older patients: Are we making progress?
Elihu H. Estey · 2009 · Best Practice & Research Clinical Haematology
Treating acute myeloid leukemia in the modern era: A primer
William G. Blum, Alice S. Mims · 2020 · Cancer
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
Yao Qin, Pu Kuang, Ting Liu · 2022 · Clinical and Experimental Medicine
All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia
Yan Chen, Xia Tong, Rongyuan Lu, Zhengfu Zhang, Tao Ma · 2024 · Frontiers in Pharmacology
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Kenny Tang, Andre C. Schuh, Karen W L Yee · 2021 · Current Oncology Reports
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
Sylvain Garciaz, Colombe Saillard, Yosr Hicheri, Norbert Vey · 2021 · Cancers
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
Judith E. Karp, Tatiana I. Vener, Mitch Raponi, Ellen Kelly Ritchie, Benjamin D. Smith, Steven D. Gore, Lawrence E. Morris, Eric Jay Feldman, Jacqueline M. Greer, Sami N. Malek et al. · 2011 · Blood
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis
A Stone, Tsila Zuckerman, Liat Flaishon, Ruth Ben Yakar, Jacob M. Rowe · 2019 · Leukemia Research
[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)].
2017 · PubMed Central
New insights in the management of elderly patients with acute myeloid leukemia
Hervé Dombret, Emmanuel Raffoux, Claude Gardin · 2009 · Current Opinion in Oncology
Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine
Mathilde Gavillet, Jasmine Noetzli, Sabine Blum, Michel André Duchosal, Olivier Spertini, J.-F. Lambert · 2012 · Haematologica
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))
Yasemin Küley-Bagheri, Karl‐Anton Kreuzer, Ina Monsef, Michael Lübbert, Nicole Skoetz · 2018 · Cochrane Database of Systematic Reviews
Targeted Alpha-Particle Therapy for Hematologic Malignancies
Joseph Gerard Jurcic · 2019 · Journal of medical imaging and radiation sciences
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Jean El Cheikh, Ghassan Bidaoui, Mustafa Saleh, Nour M. Moukalled, Iman Abou Dalle, Ali A. Bazarbachi · 2023 · Clinical Hematology International
The Role of Decitabine for the Treatment of Acute Myeloid Leukemia
Alex Ganetsky · 2012 · Annals of Pharmacotherapy
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia
Nathaniel J. Buteyn, Kavin Fatehchand, Ramasamy Santhanam, Huiqing Fang, Gino M Dettorre, Shalini Gautam, Bonnie K. Harrington, Sally E. Henderson, Giovanna Merchand‐Reyes, Xiaokui Molly Mo et al. · 2018 · International Immunology
Volasertib for the Treatment of Acute Myeloid Leukemia: A Review of Preclinical and Clinical Development
Melanie Janning, Walter Fiedler · 2014 · Future Oncology
The evolving landscape in the therapy of acute myeloid leukemia
Grace L. Peloquin, Yi‐Bin Chen, Amir Tahmasb Fathi · 2013 · Protein & Cell
Retinoids in cancer chemoprevention and therapy: Meta-analysis of randomized controlled trials
Shuting Chen, Qinchao Hu, Xiaoan Tao, Juan Xia, Tong Wu, Bin Cheng, Juan Wang · 2022 · Frontiers in Genetics
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
Farhad Ravandi, Jacqueline J Cloos, Francesco Buccisano, Richard James Dillon, Konstanze Döhner, Sylvie D. Freeman, Christopher Simon Hourigan, G. J. Ossenkoppele, Gail J. Roboz, Marion Subklewe et al. · 2023 · American Journal of Hematology
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)
Jose Francisco Falantes, Lisa Pleyer, Sylvain Thépot, Antonio Medina Almeida, Luca Maurillo, Violeta Martínez‐Robles, Reinhard Stauder, Raphaël Itzykson, Ricardo Pinto, Adriano Venditti et al. · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
Shifting paradigms in the treatment of older adults with AML
Thomas William LeBlanc, Harry Paul Erba · 2019 · Seminars in Hematology
Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
Tristan E. Knight, Holly J. Edwards, Jeffrey Warren Taub, Yubin Ge · 2019 · Cancer Management and Research
Glasdegib in the Treatment of Acute Myeloid Leukemia
Anna Wolska, Tadeusz Robak · 2019 · Future Oncology
Updates on DNA methylation modifiers in acute myeloid leukemia
Bruna Contieri, Bruno Kosa Lino Duarte, Mariana Lazarini · 2020 · Annals of Hematology
Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
Norbert Vey · 2020 · Therapeutic Advances in Hematology
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Rory Michael Shallis, Daniel Aaron Pollyea, Amer Methqal Zeidan · 2021 · Blood Reviews
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
Abhishek Maiti, Marina Y. Konopleva · 2022 · The Cancer Journal
Primary Vaginal Myeloid Sarcoma: A Rare Case Report and Review of the Literature
Gaurang Modi, Irappa Madabhavi, Harsha P. Panchal, Apurva Patel, Asha Anand, Sonia Parikh, Pritam Jain, Swaroop Revannasiddaiah, Malay S. Sarkar · 2015 · Case Reports in Obstetrics and Gynecology
Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy
Michael Lübbert, Carsten Müller‐Tidow, Wolf‐Karsten Hofmann, Harold Phillip Koeffler · 2008 · Journal of Cellular Biochemistry
Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?
Galina Tsykunova, Håkon Reikvam, Aymen Bushra Ahmed, Ina Nepstad, Bjørn Tore Gjertsen, Øystein Bruserud · 2012 · Expert Opinion on Investigational Drugs
Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review
Khadega Ahmed Abuelgasim, Bandar Albuhayri, Rayan Munshi, Areej Al Mugairi, Bader Alahmari, Giamal Edin Mohamed Gmati, Hind Salama, Mohsen Alzahrani, Ayman Alhejazi, Ahmed S. Alaskar et al. · 2020 · Leukemia Research Reports
Selected Drugs with Reported Secondary Cell-Differentiating Capacity Prime Latent HIV-1 Infection for Reactivation
Takao Shishido, Frank Wolschendorf, Alexandra Emilie Duverger, Frederic Wagner, John C. Kappes, Jennifer Jones, Olaf Kutsch · 2012 · Journal of Virology
Treating octogenarian and nonagenarian acute myeloid leukemia patients—Predictive prognostic models
Antoine Joseph Harb, Wei Chang Colin Tan, Gregory E. Wilding, LaurieAnn Ford, Sheila N.J. Sait, AnneMarie W. Block, Maurice P Barcos, Paul K. Wallace, Eunice S. Wang, Meir Wetzler · 2009 · Cancer
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07)
Jakob Robert Passweg, Thomas Pabst, Sabine Blum, Mario J. Bargetzi, Qiyu Li, Dominik A. Heim, Georg Stüssi, Michael Gregor, Leda Leoncini, Sandrine Meyer‐Monard et al. · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic
Muneera Al-Hussaini, John F. DiPersio · 2014 · Expert Review of Hematology
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases
Hanne Fredly, Camilla Stapnes, Bjørn Tore Gjertsen, Øystein Bruserud · 2010 · Hematology
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts
Sa A. Wang, Keyur Pravinchandra Patel, Olga Pozdnyakova, Jie Peng, Zhuang Zuo, Paola Dal Cin, David P. Steensma, Robert Paul Hasserjian · 2016 · Modern Pathology
Pharmacokinetic evaluation of decitabine for the treatment of leukemia
Jeffrey Bryan, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Elias Joseph Jabbour · 2011 · Expert Opinion on Drug Metabolism & Toxicology
TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE
Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Pleșa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Emmanuel Nicolini, Claudiu Plesa et al. · 2015 · Mediterranean Journal of Hematology and Infectious Diseases
The FLAMSA concept—past and future
Hans‐Jochem Kolb, Christoph Schmid · 2020 · Annals of Hematology
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
Harry Paul Erba, Megan K. D. Othus, Roland B. Walter, Mark H. Kirschbaum, Martin S. Tallman, Richard A. Larson, Marilyn L. Slovak, Kenneth J. Kopecky, Holly M. Gundacker, Frederick R. Appelbaum · 2013 · Leukemia Research
A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Xavier Thomas, Christopher Kevin Arthur, Jacques Delaunay, Mark Jones, Erhan Berrak, Hagop M. Kantarjian · 2013 · Clinical Lymphoma Myeloma & Leukemia
The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia
Francesco Buccisano, Christopher Simon Hourigan, Roland B. Walter · 2017 · Current Hematologic Malignancy Reports
Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia
Laura Christian Michaelis, Heidi D. Klepin, Roland B. Walter · 2018 · Expert Opinion on Pharmacotherapy
Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
Jochen J. Frietsch, Friederike Hunstig, Christoph Wittke, Christian Junghanß, Tobias Franiel, Sebastian Scholl, Andreas Hochhaus, Inken Hilgendorf · 2020 · Bone Marrow Transplantation
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options
Daniel R. Richardson, Steven Daniel Green, Matthew Charles Foster, Joshua F. Zeidner · 2021 · Current Hematologic Malignancy Reports
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
Mike Dennis, Ian Thomas, Cono A. Ariti, Laura Upton, Alan K. Burnett, Amanda Gilkes, Rohini Radia, Claire Jane Hemmaway, Priyanka Mehta, Steven Knapper et al. · 2021 · Blood Advances
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
Aziz Nazha, Carlos Bueso-Ramos, Elihu H. Estey, Stefan H Faderl, Susan Mary O'Brien, Michael H. Fernandez, Martin H. Nguyen, Charles Asa Koller, Emil J. Freireich, Miloslav Beran et al. · 2013 · Frontiers in Oncology
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
Koichi Takahashi, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Gautam M. Borthakur, Tapan Mahendra Kadia, Courtney Denton Dinardo, Elias Joseph Jabbour, Sherry A. Pierce, Zeev E. Estrov, Marina Y Konopleva et al. · 2015 · Clinical Lymphoma Myeloma & Leukemia
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))
Yasemin Küley-Bagheri, Karl‐Anton Kreuzer, Andreas Engert, Nicole Skoetz · 2015 · Cochrane Database of Systematic Reviews
All-trans retinoic acid in anticancer therapy: how nanotechnology can enhance its efficacy and resolve its drawbacks
Gabriel Silva Marques Borges, Flávia Alves Lima, Guilherme Carneiro, Gisele Assis Castro Goulart, Lucas Antônio Miranda Ferreira · 2021 · Expert Opinion on Drug Delivery
Outcomes of elderly de novo acute myeloid leukemia treated by a risk‐adapted approach based on age, comorbidity, and performance status
Jae‐Ho Yoon, Byung‐Sik Cho, Hee‐Je Kim, Jung Ho Kim, Seung‐Hwan Shin, Seung‐Ah Yahng, Sung‐Eun Lee, Ki‐Seong Eom, Yoo‐Jin Kim, Seok Lee et al. · 2013 · American Journal of Hematology
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki, Courtney Denton Dinardo, Naval Guastad Daver, Musa E. Yilmaz, Hussein A. Abbas et al. · 2023 · American Journal of Hematology
Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
Richard L. Momparler, Sylvie Côté, Louise F. Momparler · 2013 · Leukemia Research
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia
Jie Jin, Jian Chen, Shanshan Suo, Wenbin Qian, Haitao Meng, Wenyuan Mai, Hongyan Tong, Jian Huang, Wenjuan Yu, Juyin Wei et al. · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia.
Johnnie J. Orozco, Frederick R. Appelbaum · 2012 · PubMed
Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia
Santhosh K. Sadashiv, Christie J. Hilton, Cyrus Khan, James M. Rossetti, Heather L. Benjamin, Salman Fazal, Entezam Sahovic, Richard K. Shadduck, JOHN W. LISTER · 2014 · Cancer Medicine
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
Marlise Rachael Luskin, Daniel J. DeAngelo · 2017 · Expert Review of Hematology
Treatment of Unfit Patients With Acute Myeloid Leukemia: A Still Open Clinical Challenge
Felicetto Ferrara · 2011 · Clinical Lymphoma Myeloma & Leukemia
The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia
Rory Michael Shallis, Prajwal Chaitanya Boddu, Jan Philipp Bewersdorf, Amer Methqal Zeidan · 2019 · Blood Reviews
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
Sonja Loges, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp‐Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto Massimo Lemoli, Daniele Giovanni Mattei, Walter Fiedler et al. · 2025 · Nature Communications
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia
Anya K. Hotinski, Ian D. Lewis, David M. Ross · 2015 · Expert Opinion on Pharmacotherapy
Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia
Jihane Fattoum, Giovanna Cannas, Mohamed Elhamri, Isabelle Tigaud, Adriana Pleșa, Maël Heiblig, Claudiu Plesa, Eric Wattel, Xavier Thomas · 2015 · Clinical Lymphoma Myeloma & Leukemia
Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy
Wei Dong Wu, Yan Lin, Lili Xiang, Weimin Dong, Xiaoying Hua, Yun Ling, Haiqian Li, Feng Yan, Xiaobao Xie, Weiying Gu · 2016 · Annals of Hematology
Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia
Susan Storey, Tamryn Fowler Gray, Ashley Leak Bryant · 2017 · Current Geriatrics Reports
Recent Progress in Interferon Therapy for Myeloid Malignancies
Fiona M. Healy, Lekh N. Dahal, Jack R.E. Jones, Yngvar Fløisand, John F. Woolley · 2021 · Frontiers in Oncology
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis
Antonia Bainschab, Franz Quehenberger, Hildegard Greinix, Robert Krause, Albert Wölfler, Heinz Sill, Armin Zebisch · 2016 · Leukemia Research
Induction therapy for elderly patients with acute myeloid leukemia
Mike G. Martin, Camille N. Abboud · 2008 · Blood Reviews
Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
Wittawat Chantkran, Ya-Ching Hsieh, Daniella I. Zheleva, Sheelagh Frame, Helen Wheadon, Mhairi Copland · 2021 · Cell Death Discovery
Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review
Nidhi Tandon, S Banavali, Hari Menon, Sumeet Gujral, P. S. Amre Kadam, Ashish Vijay Bakshi · 2013 · Indian Journal of Cancer
Has there been progress in the treatment of older patients with acute myeloid leukemia?
Harry Paul Erba · 2010 · Best Practice & Research Clinical Haematology
Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients
Jacobien R. Hilberink, Carin L. E. Hazenberg, Eva van den Berg, André B. Mulder, Jan Jacob Schuringa, Lieke H. van der Helm, Marco de Groot, Goda Choi, Geertruida H. de Bock, Edo Vellenga et al. · 2019 · Leukemia Research
Venetoclax-Based Combinations for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Tamer Adel Othman, Tali Azenkot, Benjamin Moskoff, Matthew E. Tenold, Brian Andrew Jonas · 2021 · Future Oncology
How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia
Andrew Warren Hahn, OMER HASSAN JAMY, Sara E. Nunnery, George Yaghmour, Smith Giri, Ranjan Pathak, Mike G. Martin · 2015 · Clinical Lymphoma Myeloma & Leukemia
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O6‐methylguanine DNA methyltransferase expression
Joseph M. Brandwein, Jeannine Kassis, Brian F. Leber, Donna E. Hogge, Kang Howson‐Jan, Mark David Minden, André Galarneau, Jean‐François Pouliot · 2014 · British Journal of Haematology
A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia
Rita Hleihel, Hiba El Hajj, Hsin-Chieh Wu, Caroline Berthier, Hong‐Hu Zhu, Radwan Massoud, Zaher I. Chakhachiro, Marwan Eid El-Sabban, Hugues de Thé, Ali A. Bazarbachi · 2021 · Haematologica
Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
Shannon R. McCurdy, Selina M. Luger · 2021 · Haematologica
Azacitidine in AML: a treatment option?
Gerwin A Huls · 2015 · Blood
Volasertib for AML: clinical use and patient consideration
Zhonglin Hao, Vamsi K Kota · 2015 · OncoTargets and Therapy
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes
Thomas Prébet, Thorsten Braun, Odile Beyne‐Rauzy, François Dreyfus, Aspasia Stammatoullas, Eric Wattel, Shanti Amé, Emmanuel Raffoux, Jacques Delaunay, Aude Charbonnier et al. · 2013 · Leukemia Research
Single Technology Appraisal
Anthony J. Culyer · 2014
Novel Treatment Paradigms in Acute Myeloid Leukemia
Nabin Khanal, Shristi Upadhyay Banskota, Vijaya Raj Bhatt · 2020 · Clinical Pharmacology & Therapeutics
Exploiting the Nucleotide Substrate Specificity of Repair DNA Polymerases To Develop Novel Anticancer Agents
Emmanuele Crespan, Anna Garbelli, Alessandra Amoroso, Giovanni Maga · 2011 · Molecules
One day at a time: Improving the patient experience during and after intensive chemotherapy for younger and older AML patients
Vida Ghodraty-Jabloo, Shabbir M.H. Alibhai, Henriette Breunis, Martine T.E. Puts · 2014 · Leukemia Research
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Bruno C. Medeiros, Holbrook E K Kohrt, Jason R. Gotlib, Steven E. Coutre, Bing Melody Zhang, Daniel A. Arber, James L. Zehnder · 2011 · American Journal of Hematology